AlphaRx Reports Positive Preclinical Data For GAI-122

AlphaRx has reported positive preclinical results on GAI-122 injectable nano-emulsion in multiple models of acute hepatitis.

GAI-122 reduced Aminotransferase (ALT) following IP administration in three different preclinical models of acute liver injury, said the company.

In the a-Fas model of liver injury, GAI-122 reduced ALT levels by 90% from baseline, where control ALT values were ~22,000 IU/L. Significant efficacy was also demonstrated in the rat TNFa/Gln model and in the Drug-induced liver injury (DILI) model, said the company.

Michael Weisspapir, Chief Medical Scientist of AlphaRx, said: “DILI accounts for more than 50% of acute liver failure and there are no satisfactory treatment options currently available. The excellent efficacy data demonstrated by these studies suggest that GAI-122 may represent a potential first line treatment option for patients with liver disease.”